Blood concentration of soluble Fas antigen is higher in patients with benign and malignant tumors in comparison with healthy subjects, which probably suggests its involvement into tumorigenesis. Key Words: tumors; apoptosis; soluble Fas antigenApoptosis, programmed cell death, is an important mechanism maintaining homeostasis in multicellular organisms. Disturbances in cell elimination underlie various pathological states such as malignant tumors, Alzheimer disease, multiple sclerosis, amyotrophic lateral sclerosis, thyroiditis, hepatitis, and autoimmune diseases.Fas/APO-1/CD95 is a type I transmembrane glycoprotein belonging to the TNF/NDF receptor family [5]. Fas is expressed in various tissues, in particular in the thymus, liver, heart, lungs; it is present on activated lymphocytes, natural killers, virus-infected and tumor cells.Similarly to tumor necrosis factor p55, Fas not only induces cell apoptosis upon interaction with specific ligand FasL or agonistic monoclonal antibodies (MCA) to Fas, but also activate transcription factor NtkB [14]. The mechanism triggering cell death via Fas is studied in detail. The interaction of Fas with FasL or agonistic MCA induces activation of caspase-8 or caspase-2 proteases via adapter proteins FADD/ MORT-1 or RIP and RAIDD, respectively [11,14] Molecular cloning studies and nucleotide-sequence analysis have demonstrated that apart from transmembrane Fas receptor, cells produce also soluble Fas (sFas), a product of alternative spicing of full-length Fas mRNA, which inhibits cytotoxicity induced by anti-Fas MCA in vitro [2,3]. Thus, enhanced production of sFas can underlie cell resistance to apoptosis.Elevated blood concentration of sFas was observed in some autoimmune disease: systemic lupus erythematosus [15] The aim of the present study was to determine serum concentration of sFas in patients with malignant tumors of various morphology and localization and to explore the relationship between sFas and these diseases. MATERIALS AND METHODSHybrid cells producing MCA to recombinant full-length Fas (Coultronics) were obtained according to a standard protocol [9]. Splenocytes from immunized BALB/c mice (3 intraperitoneal injections with a 2-week interval) were fused with mouse myeloma cells NSO/1
Here we present the results of evaluation of the expression of neural cell adhesion molecules CD56 (NCAM) in serous ovarian adenocarcinoma. The expression was detected in 48.5% cases. Infiltration of tumor stroma and parenchyma with CD8+ and CD4+ lymphocytes was significantly less pronounced in tumors expressing neural cell adhesion molecules; CD3+CD4+CD25+ predominate among CD4+ lymphocytes in CD56+ tumors. CD56+ tumors were lower in size (5.2±0.6, 7.9±0.8 and 10.3±1.5 cm in monomorphic, mosaic, and negative phenotypes, respectively (p=0.05) and were characterized by the absence of cystic component (p=0.012), larger disseminations in the peritoneum (4.2±1.1 and 2.7±0.5 cm; p=0.05), and larger volume of the residual tumor (p=0.018) after surgical treatment. NCAM phenotype of the tumor does not correlate with the stage and differentiation degree of serous ovarian adenocarcinoma.
For many years ovarian cancer (OC) has remained the leading cause of mortality from gynecological cancer diseases. The problem of late diagnosis of ovarian cancer remains still unresolved in more than 70% of patients when the diagnosis is established at advanced stages. The standard approach to the treatment of patients is to perform surgical removal of the tumor at the first stage, which often pursues both therapeutic and diagnostic purposes, as it allows performing the disease restaging and assessing its prevalence. To date, the question of the relevance of implementation and the extent of lymph node dissection still remains open. In this regard, in this article, we want to present the available evidence base regarding the use of the performing retroperitoneal lymph node dissection in advanced OC patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.